Issued Patents All Time
Showing 1–16 of 16 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 11419856 | Pharmaceutical combinations for use in the treatment of neoplastic diseases | Felix Bachmann, Paul M.J. McSheehy | 2022-08-23 |
| 10724072 | Use of phospho-Akt as a biomarker of drug response | Felix Bachmann | 2020-07-28 |
| 10656162 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | Felix Bachmann | 2020-05-19 |
| 10487075 | Substituted mono- and polyazanaphthalene derivatives and their use | Jens Pohlmann, Martin Stieger, Stefan Reinelt | 2019-11-26 |
| 10222377 | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | Felix Bachmann, Madlaina Breuleux, Michael Boutros, Daniel Gilbert, Xian Zhang | 2019-03-05 |
| 10067120 | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles | Felix Bachmann | 2018-09-04 |
| 10006078 | Use of phospho-Akt as a biomarker of drug response | Felix Bachmann | 2018-06-26 |
| 9995754 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | Felix Bachmann | 2018-06-12 |
| 9970938 | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | Felix Bachmann, Madlaina Breuleux, Michael Boutros, Daniel Gilbert, Xian Zhang | 2018-05-15 |
| 9476889 | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles | Felix Bachmann | 2016-10-25 |
| 9366682 | Use of stathmin as a biomarker of drug response to furazanobenzimidazoles | Felix Bachmann | 2016-06-14 |
| 8877771 | Treatment of solid tumors with rapamycin derivatives | Terence O'Reilly, Jeanette Marjorie Wood | 2014-11-04 |
| 8778962 | Treatment of solid tumors with rapamycin derivatives | Terence O'Reilly, Jeanette Marjorie Wood | 2014-07-15 |
| 8436010 | Treatment of solid tumors with rapamycin derivatives | Terence O'Reilly, Jeanette Marjorie Wood | 2013-05-07 |
| 8410131 | Cancer treatment | Terence O'Reilly, Jeanette Marjorie Wood | 2013-04-02 |
| 7749698 | p53 wild-type as biomarker for the treatment with mTOR inhibitors in combination with a cytotoxic agent | Iwan Beuvink, Anne Boulay, Terence O'Reilly, George Thomas | 2010-07-06 |